We recently published 10 Big Names With Surprising Gains. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Wednesday’s best performers.
Viking Therapeutics bounced back by 5.46 percent on Wednesday to finish at $25.69 apiece as investors resorted to early bargain-hunting to take advantage of its cheap valuations.
This followed the company’s 42-percent decline on Tuesday, dragged by results of its weight loss clinical trial that saw a huge dropout rate in the number of enrollees due to mild to moderate adverse effects, including nausea and vomiting.
In a statement, Viking Therapeutics, Inc. (NASDAQ:VKTX) said it registered a 28-percent dropout rate in the overall number of enrollees for the second phase of its VK2735 clinical study, sparking concerns about the drug’s tolerability.
In a call with analysts, Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Brian Lian said that GI-related adverse event rates might be further reduced through lower starting doses and or slower dose escalation.
He added that the company was looking to explore it further in an upcoming maintenance dosing study.
Following the resu
While we acknowledge the potential of VKTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
